Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial

Stefka Tyanova, Tao Xu, Mellissa Williamson, Alberto Rocci, Wan-Jen Hong, Huan Jin, Sudeep Karve, James Roose, Ahmed Sawas, Shaji Kumar

Blood (2021) 138 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2021-147713

Published: 2021

Journal Articles

Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma Using a US-Based Electronic Health Records Database

Tao Xu, Stefka Tyanova, Mellissa Williamson, Alberto Rocci, Kasra Yousefi, Shaji Kumar

Blood (2021) 138 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2021-150148

Published: 2021

Journal Articles

Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers

David Ciarlariello, Sean Harshman, Alessandro Canella, Erinn Hade, Alberto Rocci, MD, Antonio Palumbo, MD, Craig C Hofmeister, MD MPH, Michael Freitas, Don M Benson, MD PhD, Flavia Pichiorri, PhD

Blood (2015) 126 (23): 1814.

https://doi.org/10.1182/blood.V126.23.1814.1814

Published: 2015

Journal Articles

Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

Hanna Radomska, Alessandro Canella, Consiglio Jessica, Alberto Rocci, MD, Cascione Luciano, Hector Cordero, Liu Joseph, Enrico Caserta, Santhanam Ramasamy, Yvonne A. Efebera, MD MPH, Stefano Volinia, PhD, Craig C Hofmeister, MD MPH, Flavia Pichiorri, PhD

Blood (2015) 126 (23): 1791.

https://doi.org/10.1182/blood.V126.23.1791.1791

Published: 2015

Journal Articles

Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix

Siobhan Glavey, MD, Alexandra Naba, PhD, Salomon Manier, MD, Manuela Gambella, Alberto Rocci, MD, Antonio Sacco, BS, John M. Asara, PhD, Michele Moschetta, MD, Michaela R. Reagan, PhD, Yuji Mishima, PhD, Yawara Kawano, MD PhD, Aldo M Roccaro, MD PhD, Antonio Palumbo, MD, Richard O. Hynes, PhD, Irene M. Ghobrial, MD

Blood (2014) 124 (21): 2051.

https://doi.org/10.1182/blood.V124.21.2051.2051

Published: 2014

Journal Articles

In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide

Manuela Gambella, Paola Omedè, Stefania Oliva, MD, Milena Gilestro, Vittorio Emanuele Muccio, Daniela Drandi, Simone Ferrero, MD, Francesca Gay, MD, Francesca Patriarca, MD, Carmela Palladino, MD, Maria Teresa Petrucci, MD, Norbert Pescosta, MD, Anna Marina Liberati, MD, Tommaso Caravita, MD, Francesco Di Raimondo, MD, Alberto Rocci, MD, Pellegrino Musto, MD, Mario Boccadoro, MD, Antonio Palumbo, MD

Blood (2014) 124 (21): 3394.

https://doi.org/10.1182/blood.V124.21.3394.3394

Published: 2014

Journal Articles

Circulating Mir- 16 and Mir- 25 As New Prognosticators For Multiple Myeloma

Blood (2013) 122 (21): 1853.

https://doi.org/10.1182/blood.V122.21.1853.1853

Published: 2013

Journal Articles

Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients

Blood (2013) 122 (21): 3126.

https://doi.org/10.1182/blood.V122.21.3126.3126

Published: 2013

Journal Articles

A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma

Blood (2013) 122 (21): 685.

https://doi.org/10.1182/blood.V122.21.685.685

Published: 2013

Journal Articles

Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

Blood (2013) 122 (21): 2077.

https://doi.org/10.1182/blood.V122.21.2077.2077

Published: 2013

Journal Articles

miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.

Blood (2012) 120 (21): 2921.

https://doi.org/10.1182/blood.V120.21.2921.2921

Published: 2012

Journal Articles

High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma

Marco Ladetto, MD, Simone Ferrero, MD, Daniela Drandi, PhD, Paola Omedè, PhD, Francesca Patriarca, MD, Nicola Mordini, MD, Silvia Cena, PhD, Daniela Barbero, PhD, Luigia Monitillo, PhD, Luisa Giaccone, MD, Alberto Rocci, MD, Sara Barbiero, MD, Moreno Festuccia, MD, Andrea Gallamini, MD, Renato Fanin, MD, Roberto Passera, PhD, Antonio Palumbo, MD, Mario Boccadoro, MD, Benedetto Bruno, MD

Blood (2012) 120 (21): 4204.

https://doi.org/10.1182/blood.V120.21.4204.4204

Published: 2012

Journal Articles

MiR-221 and MiR-222 Patterns Characterize Burkitt Lymphoma in Human and Mouse Model

Jessica Consiglio, MS, Andrea Vecchione, MD, Marco Galasso, MS, Alberto Rocci, MD, Mario Acunzo, PhD, Maria Rosaria Sapienza, Stefano Volinia, PhD, Pier Paolo Piccaluga, Sr., MD, PhD, Rituparna De, Tiffany Talabere, Jingwen Guan, Nicola Zanesi, PhD, Carlo M. Croce, MD, Flavia Pichiorri

Blood (2012) 120 (21): 1304.

https://doi.org/10.1182/blood.V120.21.1304.1304

Published: 2012

Journal Articles

LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL

Blood (2011) 118 (21): 827.

https://doi.org/10.1182/blood.V118.21.827.827

Published: 2011

Journal Articles

High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease

Blood (2010) 116 (21): 1898.

https://doi.org/10.1182/blood.V116.21.1898.1898

Published: 2010

Journal Articles

A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients

Antonio Palumbo, Patrizia Falco, Giulia Benevolo, Davide Rossi, Angelo Michele Carella, Tommasina Guglielmelli, Alberto Rocci, Lorenzo De Paoli, Mariella Grasso, Maria Letizia Mosca Siez, Eugenio Piro, Simona Caltagirone, Francesca Gay, Federica Cavallo, Gianluca Gaidano, Mario Boccadoro

Blood (2010) 116 (21): 1940.

https://doi.org/10.1182/blood.V116.21.1940.1940

Published: 2010

Journal Articles

Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.

Blood (2010) 116 (21): 3375.

https://doi.org/10.1182/blood.V116.21.3375.3375

Published: 2010

Journal Articles

IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin

Blood (2010) 116 (21): 2951.

https://doi.org/10.1182/blood.V116.21.2951.2951

Published: 2010

Journal Articles

Are the Myeloma Bone Microevironment Cells Tumoral or Not?.

Nicola Giuliani, Francesca Novara, Katia Todoerti, Nadia Zaffaroni, Raffaella Villa, Paola Storti, Maria Ester Bernardo, Cristina Manferdini, Elena Gabusi, Manuela Abeltino, Marina Bolzoni, Luca Agnelli, Alberto Rocci, Simona Colla, Gabriella Sammarelli, Vittorio Rizzoli, Orsetta Zuffardi, Antonino Neri, Gina Lisignoli

Blood (2009) 114 (22): 1816.

https://doi.org/10.1182/blood.V114.22.1816.1816

Published: 2009

Journal Articles

Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.

Blood (2009) 114 (22): 960.

https://doi.org/10.1182/blood.V114.22.960.960

Published: 2009

NARROW

Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial

Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma Using a US-Based Electronic Health Records Database

Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers

Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development

Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix

In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide

Circulating Mir- 16 and Mir- 25 As New Prognosticators For Multiple Myeloma

Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients

A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma

Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors

miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.

High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma

MiR-221 and MiR-222 Patterns Characterize Burkitt Lymphoma in Human and Mouse Model

LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL

High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease

A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients

Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.

IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin

Are the Myeloma Bone Microevironment Cells Tumoral or Not?.

Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only